Treatment targeting the receptor or its ligand, CSF-1R/CSF-1, has been found to improve T cell responses; further, combining CSF-1R inhibition with checkpoint blockades or adoptive T cell transfer therapy resulted in an improved anti-tumor T cell activity and tumor regression [93,96,97]. The gene discussed is CSF1; the disease is neoplasm.